Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Scientists Study ‘SuperAgers,’ Make Surprising Alzheimer’s Discovery - Newsweek (opens in a new tab)

newsweek.com · 2026-07-31

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One key claim is not backed by the study. One other point was not covered by the paper.

  • 2 supported
  • 1 overstated
  • 1 not supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two claims go beyond the study. One overstates it and one isn't supported at all. One claim the study doesn't address.

  • 2 supported
  • 1 overstated
  • 1 not supported
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not supportedThe researchers examined APOE variants, three polygenic risk scores, genetic ancestry, and rare protective variants, and found no meaningful genetic differences that predicted SuperAger status.View evidenceHide evidence

Why this verdict

The APOE, three PRS, and ancestry portions are supported by the abstract-level profile, including no APOE/PRS prediction and robustness to ancestry adjustment. However, the claim that rare protective variants were examined is not supported and conflicts with the profile limitation that rare genetic variation was not evaluated. The broad statement about no meaningful genetic differences therefore goes beyond the supplied paper evidence.

1

Study evidence

APOE allele and genotype distributions did not differ between SuperAgers and cognitively average controls.

“We studied 231 participants (SuperAgers n = 142; Controls n = 89).”
2

Study evidence

Genetic ancestry structure across SuperAgers and Cognitively Average Controls was comparable.

“We confirmed that the genetic ancestry structure across groups was comparable.”
Claim 2 of 5OverstatedResearchers studying SuperAgers found that they cannot be distinguished from cognitively average peers based on inherited Alzheimer's risk genes.View evidenceHide evidence

Why this verdict

The abstract supports a narrower finding: APOE allele/genotype distributions and three contemporary AD polygenic risk scores did not differ/predict SuperAger status. The headline phrasing about inherited Alzheimer’s risk genes is broader than the paper profile at abstract depth, because the study assessed common-variant AD risk captured by APOE and PRS, not inherited AD genetic risk generally or rare variants.

1

Study evidence

APOE allele and genotype distributions did not differ between SuperAgers and cognitively average controls.

“We studied 231 participants (SuperAgers n = 142; Controls n = 89).”
Claim 3 of 5Not coveredThe story notes limitations: the study was relatively small for genetic research, was cross-sectional, and did not account for lifestyle, behavior, or blood vessel health.View evidenceHide evidence

Why this verdict

The profile at abstract depth supports that the sample was modest for genetic association work and lacks detailed precision estimates, but it does not verify the story’s stated limitations that the analysis was cross-sectional or that lifestyle, behavior, or vascular health were not accounted for. The abstract also describes prospective cohort enrollment, so full-text evidence would be needed to reconcile those details.

1

Study evidence

APOE allele and genotype distributions did not differ between SuperAgers and cognitively average controls.

“We studied 231 participants (SuperAgers n = 142; Controls n = 89).”
2

Study evidence

Genetic ancestry structure across SuperAgers and Cognitively Average Controls was comparable.

“We confirmed that the genetic ancestry structure across groups was comparable.”
Claim 4 of 5SupportedThe article says the findings suggest that exceptional memory later in life depends on something other than simply avoiding Alzheimer's genetic risk factors.View evidenceHide evidence

Why this verdict

As a hedged interpretation, this is consistent with the paper’s abstract-level conclusion that SuperAger status is not explained by common-variant AD genetic risk captured by APOE or contemporary PRS, motivating study of rare variants and experiential/environmental factors. The support is strongest if the phrase is understood as referring to the tested common AD risk measures, not all genetic risk factors.

1

Study evidence

APOE allele and genotype distributions did not differ between SuperAgers and cognitively average controls.

“We studied 231 participants (SuperAgers n = 142; Controls n = 89).”
Claim 5 of 5SupportedThe study examined 231 adults aged 80 or older, including 142 SuperAgers and 89 healthy controls with average memory for their age.View evidenceHide evidence

As stated231 adults; 142 SuperAgers; 89 controls

Why this verdict

The abstract explicitly reports 231 participants, including 142 SuperAgers and 89 controls, with participants aged 80 or older under the SuperAger definition.

1

Study evidence

APOE allele and genotype distributions did not differ between SuperAgers and cognitively average controls.

“We studied 231 participants (SuperAgers n = 142; Controls n = 89).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important limitation: rare genetic variation was not evaluated; the paper instead suggests rare variants as a topic for future study.

    This limitation is not acknowledged in the story presentation. More importantly, claim c3 says rare protective variants were examined, which conflicts with the abstract-level paper profile.

    From Prospective cohort genetic association (case/control-like comparison)

5 things the story did carry across
  • Primary analysis tested whether common-variant Alzheimer’s disease genetic risk, specifically APOE and three GWAS-derived polygenic risk scores, predicted SuperAger status.
  • Study sample consisted of 231 participants: 142 SuperAgers and 89 cognitively average controls.
  • APOE allele/genotype distributions did not differ between SuperAgers and controls, and none of the three PRS predicted SuperAger status in adjusted logistic regression models.
  • Genetic ancestry structure was comparable between groups, and ancestry adjustments using global ancestry fractions or principal components did not change the results.
  • Important limitation: the abstract does not report odds ratios, confidence intervals, p-values, or model-fit measures, limiting assessment of precision and the ability to rule out smaller effects.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether lower inherited common-variant Alzheimer’s disease (AD) genetic risk (APOE and contemporary AD polygenic risk scores) predicts SuperAger status in a prospectively enrolled multisite SuperAging cohort, including evaluation across genetic ancestries.Prospective cohort genetic association (case/control-like comparison)Expand

In plain English

In a prospectively enrolled multisite SuperAging cohort (n=231; SuperAgers n=142, Controls n=89), the authors tested whether common-variant AD genetic risk (APOE alleles and three contemporary AD polygenic risk scores from large GWAS) predicts SuperAger status using logistic regression adjusted for age, sex, and education and accounting for genetic ancestry. APOE allele/genotype distributions did not differ between groups, and neither APOE nor any of the three PRS predicted SuperAger status; results were unchanged after accounting for global non-European or African ancestry or principal components. The authors conclude that SuperAger status is not explained by common-variant AD genetic risk captured by APOE or contemporary PRS, suggesting investigation of rare variants and experiential factors.

Key findings

  • APOE allele and genotype distributions did not differ between SuperAgers and cognitively average controls.
  • None of three contemporary AD polygenic risk scores (PRSLambert, PRSWightman, PRSBellenguez) predicted SuperAger status in adjusted logistic regression models.
“We studied 231 participants (SuperAgers n = 142; Controls n = 89).”
What this piece can’t prove
  • Study assessed only common-variant genetic risk (APOE and contemporary GWAS-derived PRS); rare genetic variation was not evaluated.
  • Abstract does not report effect estimates (e.g., odds ratios), confidence intervals, or p-values for the reported null associations, limiting assessment of statistical precision.

1 further detail could not be confirmed from the summary.

2secondary dataCharacterize and confirm comparability of genetic ancestry structure between SuperAgers and cognitively average controls and assess robustness of genetic-risk findings to ancestry adjustments/interactions (global ancestry fractions, PCs).Genetic ancestry inference / population structure assessmentExpand

In plain English

The authors report that genetic ancestry structure was comparable between SuperAgers (n=142) and Cognitively Average Controls (n=89) in the SuperAging Research Initiative cohort, and that including global ancestry fractions or principal components in association models did not change the genetic-risk (APOE/PRS) results.

Key findings

  • Genetic ancestry structure across SuperAgers and Cognitively Average Controls was comparable.
  • Ancestry adjustments (global non-European or African ancestry fractions and principal components) did not change the genetic-risk (APOE/PRS) results.
“We confirmed that the genetic ancestry structure across groups was comparable.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

And 32 more candidates considered.